Ultrasensitive interferons quantification reveals different cytokine profile secretion in inflammatory myopathies and can serve as biomarkers of activity in dermatomyositis
ObjectiveThe objective of this study was to evaluate the presence of different types of interferon in idiopathic inflammatory myopathies (IIM) and their subgroups using ultrasensitive cytokine detection techniques (SIMOA) and to assess their potential as activity biomarkers.MethodsDisease activity w...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1529582/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823856562963218432 |
|---|---|
| author | Loïs Bolko Loïs Bolko Loïs Bolko Céline Anquetil Céline Anquetil Alba Llibre Solène Maillard Damien Amelin Karim Dorgham Vincent Bondet Océane Landon-Cardinal Océane Landon-Cardinal Océane Landon-Cardinal Ségolène Toquet Ségolène Toquet Kuberaka Mariampillai Samuel Malatre Alexandrine Mahoudeau Baptiste Hervier Mathieu Rodero Guy Gorochov Darragh Duffy Olivier Benveniste Olivier Benveniste Yves Allenbach Yves Allenbach |
| author_facet | Loïs Bolko Loïs Bolko Loïs Bolko Céline Anquetil Céline Anquetil Alba Llibre Solène Maillard Damien Amelin Karim Dorgham Vincent Bondet Océane Landon-Cardinal Océane Landon-Cardinal Océane Landon-Cardinal Ségolène Toquet Ségolène Toquet Kuberaka Mariampillai Samuel Malatre Alexandrine Mahoudeau Baptiste Hervier Mathieu Rodero Guy Gorochov Darragh Duffy Olivier Benveniste Olivier Benveniste Yves Allenbach Yves Allenbach |
| author_sort | Loïs Bolko |
| collection | DOAJ |
| description | ObjectiveThe objective of this study was to evaluate the presence of different types of interferon in idiopathic inflammatory myopathies (IIM) and their subgroups using ultrasensitive cytokine detection techniques (SIMOA) and to assess their potential as activity biomarkers.MethodsDisease activity was measured at the time of serum collection and assessed by manual muscle testing eight (MMT8 score 0-150), muscle enzymes to calculate the Physician Global Assessment (PGA) (0-10). Patients were classified as active if PGA>5.Serum IFN-α and IFN-γ levels was measured using the single molecule array (SIMOA) technique. Serum IFN-β level was measured by Elisa. Correlation between IFN levels and disease activity were performed.ResultsWe included 242 IIM patients and found a good correlation between type I Interferon (IFN) and dermatomyositis disease activity. IFN-α and IFN-β was highly correlated with disease activity (r=0.76 and r=0,58). To evaluate whether the different types of Interferons could serve as biomarkers of activity, we generated ROC curves. Patients with active DM had a higher median IFN-α level (0.49 pg/ml [0.1-3.7]) compared with non-active patients (0.03 pg/ml [0.01-0.07] p<0.05). The area under the curve was 0.90 IC95 (0.76-0.97) p<0.05. Furthermore, Myositis-specific antibodies appear to be associated with a different secretion profile; patients with anti-MDA 5 antibodies had higher level of IFN-α than most other antibodies (6.58 vs 0.14 p<0.005). NXP2 had higher IFN-β level than patients with Tif1γ antibodies.ConclusionSerum IFN-α level measured by SIMOA is a reliable biomarker of DM activity. Myositis-specific antibodies appear to be associated with a different secretion profile. This data needs to be confirmed in order to select the good therapeutics strategies in DM. |
| format | Article |
| id | doaj-art-22ba6f2176fc4672b872ab71b0d977a0 |
| institution | Kabale University |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-22ba6f2176fc4672b872ab71b0d977a02025-02-12T07:26:15ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-02-011610.3389/fimmu.2025.15295821529582Ultrasensitive interferons quantification reveals different cytokine profile secretion in inflammatory myopathies and can serve as biomarkers of activity in dermatomyositisLoïs Bolko0Loïs Bolko1Loïs Bolko2Céline Anquetil3Céline Anquetil4Alba Llibre5Solène Maillard6Damien Amelin7Karim Dorgham8Vincent Bondet9Océane Landon-Cardinal10Océane Landon-Cardinal11Océane Landon-Cardinal12Ségolène Toquet13Ségolène Toquet14Kuberaka Mariampillai15Samuel Malatre16Alexandrine Mahoudeau17Baptiste Hervier18Mathieu Rodero19Guy Gorochov20Darragh Duffy21Olivier Benveniste22Olivier Benveniste23Yves Allenbach24Yves Allenbach25Rheumatology, Maison Blanche Hospital, Reims, FranceDepartment of Internal Medicine and Clinical Immunology, National Reference Center for Rare NeuroMuscular Disorders, Pitié-Salpêtrière Hospital, Paris, FranceSorbonne Université, Institut National de la Santé et de la Recherche Médicale (INSERM), Association Institut de Myologie, Center of Research in Myology, UMRS, Paris, FranceDepartment of Internal Medicine and Clinical Immunology, National Reference Center for Rare NeuroMuscular Disorders, Pitié-Salpêtrière Hospital, Paris, FranceSorbonne Université, Institut National de la Santé et de la Recherche Médicale (INSERM), Association Institut de Myologie, Center of Research in Myology, UMRS, Paris, FranceTranslational Immunology Unit, Institut Pasteur, Université Paris Cité, Paris, FranceSorbonne Université, Institut National de la Santé et de la Recherche Médicale (INSERM), Association Institut de Myologie, Center of Research in Myology, UMRS, Paris, FranceSorbonne Université, Institut National de la Santé et de la Recherche Médicale (INSERM), Association Institut de Myologie, Center of Research in Myology, UMRS, Paris, FranceSorbonne Université, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Assistance Publique Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Paris, FranceTranslational Immunology Unit, Institut Pasteur, Université Paris Cité, Paris, FranceDepartment of Internal Medicine and Clinical Immunology, National Reference Center for Rare NeuroMuscular Disorders, Pitié-Salpêtrière Hospital, Paris, FranceDepartment of Medicine, University of Montreal, Montreal, QC, CanadaDivision of Rheumatology, Centre Hospitalier de l’Université de Montréal (CHUM), Montreal, QC, CanadaDepartment of Internal Medicine and Clinical Immunology, National Reference Center for Rare NeuroMuscular Disorders, Pitié-Salpêtrière Hospital, Paris, FranceSorbonne Université, Institut National de la Santé et de la Recherche Médicale (INSERM), Association Institut de Myologie, Center of Research in Myology, UMRS, Paris, FranceDepartment of Internal Medicine and Clinical Immunology, National Reference Center for Rare NeuroMuscular Disorders, Pitié-Salpêtrière Hospital, Paris, FranceSorbonne Université, Institut National de la Santé et de la Recherche Médicale (INSERM), Association Institut de Myologie, Center of Research in Myology, UMRS, Paris, FranceSorbonne Université, Institut National de la Santé et de la Recherche Médicale (INSERM), Association Institut de Myologie, Center of Research in Myology, UMRS, Paris, FranceDepartment of Internal Medicine and Clinical Immunology, National Reference Center for Rare NeuroMuscular Disorders, Pitié-Salpêtrière Hospital, Paris, FranceLaboratory of Pharmacological and Toxicological Chemistry and Biochemistry, Centre National de la Recherche Scientifique (CNRS), Paris Cité University, Paris, FranceSorbonne Université, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Assistance Publique Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Paris, FranceTranslational Immunology Unit, Institut Pasteur, Université Paris Cité, Paris, FranceDepartment of Internal Medicine and Clinical Immunology, National Reference Center for Rare NeuroMuscular Disorders, Pitié-Salpêtrière Hospital, Paris, FranceSorbonne Université, Institut National de la Santé et de la Recherche Médicale (INSERM), Association Institut de Myologie, Center of Research in Myology, UMRS, Paris, FranceDepartment of Internal Medicine and Clinical Immunology, National Reference Center for Rare NeuroMuscular Disorders, Pitié-Salpêtrière Hospital, Paris, FranceSorbonne Université, Institut National de la Santé et de la Recherche Médicale (INSERM), Association Institut de Myologie, Center of Research in Myology, UMRS, Paris, FranceObjectiveThe objective of this study was to evaluate the presence of different types of interferon in idiopathic inflammatory myopathies (IIM) and their subgroups using ultrasensitive cytokine detection techniques (SIMOA) and to assess their potential as activity biomarkers.MethodsDisease activity was measured at the time of serum collection and assessed by manual muscle testing eight (MMT8 score 0-150), muscle enzymes to calculate the Physician Global Assessment (PGA) (0-10). Patients were classified as active if PGA>5.Serum IFN-α and IFN-γ levels was measured using the single molecule array (SIMOA) technique. Serum IFN-β level was measured by Elisa. Correlation between IFN levels and disease activity were performed.ResultsWe included 242 IIM patients and found a good correlation between type I Interferon (IFN) and dermatomyositis disease activity. IFN-α and IFN-β was highly correlated with disease activity (r=0.76 and r=0,58). To evaluate whether the different types of Interferons could serve as biomarkers of activity, we generated ROC curves. Patients with active DM had a higher median IFN-α level (0.49 pg/ml [0.1-3.7]) compared with non-active patients (0.03 pg/ml [0.01-0.07] p<0.05). The area under the curve was 0.90 IC95 (0.76-0.97) p<0.05. Furthermore, Myositis-specific antibodies appear to be associated with a different secretion profile; patients with anti-MDA 5 antibodies had higher level of IFN-α than most other antibodies (6.58 vs 0.14 p<0.005). NXP2 had higher IFN-β level than patients with Tif1γ antibodies.ConclusionSerum IFN-α level measured by SIMOA is a reliable biomarker of DM activity. Myositis-specific antibodies appear to be associated with a different secretion profile. This data needs to be confirmed in order to select the good therapeutics strategies in DM.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1529582/fullinterferondermatomyositisimmune mediated necrotizing myopathieAnti-synthetase syndrominclusion body myositisbiomarker |
| spellingShingle | Loïs Bolko Loïs Bolko Loïs Bolko Céline Anquetil Céline Anquetil Alba Llibre Solène Maillard Damien Amelin Karim Dorgham Vincent Bondet Océane Landon-Cardinal Océane Landon-Cardinal Océane Landon-Cardinal Ségolène Toquet Ségolène Toquet Kuberaka Mariampillai Samuel Malatre Alexandrine Mahoudeau Baptiste Hervier Mathieu Rodero Guy Gorochov Darragh Duffy Olivier Benveniste Olivier Benveniste Yves Allenbach Yves Allenbach Ultrasensitive interferons quantification reveals different cytokine profile secretion in inflammatory myopathies and can serve as biomarkers of activity in dermatomyositis Frontiers in Immunology interferon dermatomyositis immune mediated necrotizing myopathie Anti-synthetase syndrom inclusion body myositis biomarker |
| title | Ultrasensitive interferons quantification reveals different cytokine profile secretion in inflammatory myopathies and can serve as biomarkers of activity in dermatomyositis |
| title_full | Ultrasensitive interferons quantification reveals different cytokine profile secretion in inflammatory myopathies and can serve as biomarkers of activity in dermatomyositis |
| title_fullStr | Ultrasensitive interferons quantification reveals different cytokine profile secretion in inflammatory myopathies and can serve as biomarkers of activity in dermatomyositis |
| title_full_unstemmed | Ultrasensitive interferons quantification reveals different cytokine profile secretion in inflammatory myopathies and can serve as biomarkers of activity in dermatomyositis |
| title_short | Ultrasensitive interferons quantification reveals different cytokine profile secretion in inflammatory myopathies and can serve as biomarkers of activity in dermatomyositis |
| title_sort | ultrasensitive interferons quantification reveals different cytokine profile secretion in inflammatory myopathies and can serve as biomarkers of activity in dermatomyositis |
| topic | interferon dermatomyositis immune mediated necrotizing myopathie Anti-synthetase syndrom inclusion body myositis biomarker |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1529582/full |
| work_keys_str_mv | AT loisbolko ultrasensitiveinterferonsquantificationrevealsdifferentcytokineprofilesecretionininflammatorymyopathiesandcanserveasbiomarkersofactivityindermatomyositis AT loisbolko ultrasensitiveinterferonsquantificationrevealsdifferentcytokineprofilesecretionininflammatorymyopathiesandcanserveasbiomarkersofactivityindermatomyositis AT loisbolko ultrasensitiveinterferonsquantificationrevealsdifferentcytokineprofilesecretionininflammatorymyopathiesandcanserveasbiomarkersofactivityindermatomyositis AT celineanquetil ultrasensitiveinterferonsquantificationrevealsdifferentcytokineprofilesecretionininflammatorymyopathiesandcanserveasbiomarkersofactivityindermatomyositis AT celineanquetil ultrasensitiveinterferonsquantificationrevealsdifferentcytokineprofilesecretionininflammatorymyopathiesandcanserveasbiomarkersofactivityindermatomyositis AT alballibre ultrasensitiveinterferonsquantificationrevealsdifferentcytokineprofilesecretionininflammatorymyopathiesandcanserveasbiomarkersofactivityindermatomyositis AT solenemaillard ultrasensitiveinterferonsquantificationrevealsdifferentcytokineprofilesecretionininflammatorymyopathiesandcanserveasbiomarkersofactivityindermatomyositis AT damienamelin ultrasensitiveinterferonsquantificationrevealsdifferentcytokineprofilesecretionininflammatorymyopathiesandcanserveasbiomarkersofactivityindermatomyositis AT karimdorgham ultrasensitiveinterferonsquantificationrevealsdifferentcytokineprofilesecretionininflammatorymyopathiesandcanserveasbiomarkersofactivityindermatomyositis AT vincentbondet ultrasensitiveinterferonsquantificationrevealsdifferentcytokineprofilesecretionininflammatorymyopathiesandcanserveasbiomarkersofactivityindermatomyositis AT oceanelandoncardinal ultrasensitiveinterferonsquantificationrevealsdifferentcytokineprofilesecretionininflammatorymyopathiesandcanserveasbiomarkersofactivityindermatomyositis AT oceanelandoncardinal ultrasensitiveinterferonsquantificationrevealsdifferentcytokineprofilesecretionininflammatorymyopathiesandcanserveasbiomarkersofactivityindermatomyositis AT oceanelandoncardinal ultrasensitiveinterferonsquantificationrevealsdifferentcytokineprofilesecretionininflammatorymyopathiesandcanserveasbiomarkersofactivityindermatomyositis AT segolenetoquet ultrasensitiveinterferonsquantificationrevealsdifferentcytokineprofilesecretionininflammatorymyopathiesandcanserveasbiomarkersofactivityindermatomyositis AT segolenetoquet ultrasensitiveinterferonsquantificationrevealsdifferentcytokineprofilesecretionininflammatorymyopathiesandcanserveasbiomarkersofactivityindermatomyositis AT kuberakamariampillai ultrasensitiveinterferonsquantificationrevealsdifferentcytokineprofilesecretionininflammatorymyopathiesandcanserveasbiomarkersofactivityindermatomyositis AT samuelmalatre ultrasensitiveinterferonsquantificationrevealsdifferentcytokineprofilesecretionininflammatorymyopathiesandcanserveasbiomarkersofactivityindermatomyositis AT alexandrinemahoudeau ultrasensitiveinterferonsquantificationrevealsdifferentcytokineprofilesecretionininflammatorymyopathiesandcanserveasbiomarkersofactivityindermatomyositis AT baptistehervier ultrasensitiveinterferonsquantificationrevealsdifferentcytokineprofilesecretionininflammatorymyopathiesandcanserveasbiomarkersofactivityindermatomyositis AT mathieurodero ultrasensitiveinterferonsquantificationrevealsdifferentcytokineprofilesecretionininflammatorymyopathiesandcanserveasbiomarkersofactivityindermatomyositis AT guygorochov ultrasensitiveinterferonsquantificationrevealsdifferentcytokineprofilesecretionininflammatorymyopathiesandcanserveasbiomarkersofactivityindermatomyositis AT darraghduffy ultrasensitiveinterferonsquantificationrevealsdifferentcytokineprofilesecretionininflammatorymyopathiesandcanserveasbiomarkersofactivityindermatomyositis AT olivierbenveniste ultrasensitiveinterferonsquantificationrevealsdifferentcytokineprofilesecretionininflammatorymyopathiesandcanserveasbiomarkersofactivityindermatomyositis AT olivierbenveniste ultrasensitiveinterferonsquantificationrevealsdifferentcytokineprofilesecretionininflammatorymyopathiesandcanserveasbiomarkersofactivityindermatomyositis AT yvesallenbach ultrasensitiveinterferonsquantificationrevealsdifferentcytokineprofilesecretionininflammatorymyopathiesandcanserveasbiomarkersofactivityindermatomyositis AT yvesallenbach ultrasensitiveinterferonsquantificationrevealsdifferentcytokineprofilesecretionininflammatorymyopathiesandcanserveasbiomarkersofactivityindermatomyositis |